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IntroductionHead and Neck Squamous Cell Carcinoma (HNSCC) is the most common type of the entire head and neck cancers, involving 90% of the total cases. Every year, there are more than 500,000 new cases of HNSCC worldwide, with 40,000 new cases and 7,890 deaths reported annually in the United States.1,2 Indonesian National Cancer Registry places the head and neck carcinoma on the fourth position among the top ten malignancies.3 The prevalence of patients with HNSCC in Dr. Hasan Sadikin General Hospital, Bandung in 2010–2014 is 22.3%.4
The inflammatory response has an important role in the development and progression of 
cancer, and inflammatory indicators may have prognostic means for different types of cancer. The neutrophil-to-lymphocyte ratio (NLR) acts as a free prognostic factor for patients with 
various types of cancer. An increase in NLR is associated with a decline in Overall Survival (OS) of several solid tumors, including HNSCC.5An increase in NLR indicates an ongoing 
inflammatory process. The NLR presents the activity index of protumor and antitumor which is easy to do because it is a routine examination in the daily clinical practice, obtained through the peripheral blood examination.6 The NLR is easily to perform in daily clinical practice. The aim of this study was to assess the prognostic value of NLR in HNSCC patients, associated with the clinical staging.
MethodsThis study was an analytical research design to assess the NLR as a prognostic factor in HNSCC patients. The inclusion criteria were early and late stage of HNSCC patients with histopathology result was SCC and had never 
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Abstract
Background: Neutrophil to lymphocyte ratio (NLR) is one of the inflammatory markers, associated with malignancies progression and metastasis, including head and neck squamous cell carcinoma (HNSCC). Neutrophil to lymphocyte ratio is presenting the activity index of protumor and antitumor. It is easy to perform in daily clinical practice, obtained from blood examination. The aim of this study was to assess the prognostic value of NLR in HNSCC patients, associated with the clinical staging.
Methods: This study was an analytic design to explore the relationship between NLR and clinical staging. The sample was collected from pre-treatment HNSCC patients who came to the Head and Neck Oncology Clinic, Dr. Hasan Sadikin General Hospital. The data consisted of disease history, ENT examination, staging determination, and blood sample examination for NLR count.
Results: In total, data on 92 HNSCC patients were collected. There was a statistically significant association between NLR with clinical staging in HNSCC (p<0.001). The higher the NLR, the higher the clinical stage, whereas the lower the NLR, (OR14.1; 95% CI 3.4–59.0).
Conclusions: There is a significant association between NLR with clinical staging in HNSCC. Further study is needed to explore NLR as a prognostic marker in HNSCC patients 
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been given therapy. The exclusion criteria were multiple carcinoma and residual or recurrent HNSCC patients. A cross-sectional study was conducted to include the data from the medical record, involving HNSCC patients.7,8 Data on history taking, physical examination, and biopsy were collected. After the positive SCC biopsy results were obtained, other data involving supporting examination were collected, such as Computed Tomography Scan (CT Scan), chest X-ray, and abdominal Ultra Sonography (USG) by the Standard Operating Procedures (SOP). Furthermore, laboratory data were collected from the Clinical Pathology Laboratory for complete 
blood count (Sysmex Automatic Hematology XT 2000i Analyzer, USA). Neutrophil to lymphocyte ratio (NLR) was used as a marker 
of subclinical inflammation, and it also presented the activity index of protumor and antitumor. The NLR was calculated by dividing the number of neutrophils percentage over the number of lymphocytes percentage. This study protocol was accepted by the Ethical Committee number is LB.04.01/A05/EC/130/IV/2018.The Chi-Square test was used for the statistical analysis and the Fisher Exact test was used for the 2x2 table. A Receiver Operating Characteristic (ROC) analysis 
Table 1 Characteristics of Head and Neck Squamous Cell Carcinoma Patients form Dr. Hasan 






n=80Gender     Male 81 (88.0) 10 (83.3) 71 (88.8) 0.632a     Female 11 (12.0) 2 (16.7) 9 (11.3)Age     Mean ± SD 58 ± 13 59 ± 17 58 ± 13 0.819bCarcinoma Location     Larynx 61 (66.3) 9 (75.0) 52 (65.0) 0.937c     Tongue 15 (16.3) 1 (8.3) 14 (17.5)     Sinonasal 8 (8.7) 1 (8.3) 7 (8.8)     Nasopharynx 4 (4.3) 1 (8.3) 3 (3.8)     Tonsil 2 (2.2) 0 (0.0) 2 (2.5)     Oropharynx 1 (1.1) 0 (0.0) 1 (1.3)     Esophagus 1 (1.1) 0 (0.0) 1 (1.3)Histopathology     Moderately differentiated 44 (47.8) 5 (41.7) 39 (48.8) 0.757c     Well-differentiated 29 (31.5) 5 (41.7) 24 (30.0)     Poorly differentiated 9 (9.8) 1 (8.3) 8 (10.0)     Non keratinizing 2 (2.2) 0 (0.0) 2 (2.5)     Basaloid SCC 3 (3.3) 0 (0.0) 3 (3.8)     Non keratinizing      moderately differentiated 2 (2.2) 0 (0.0) 2 (2.5)     Non-keratinizing poorly      differentiated 2 (2.2) 1 (8.3) 1 (1.3)     Carsinoma in situ 1 (1.1) 0 (0.0) 1 (1.3)Note:  The Chi-Square test was used for the statistical analysis of this study. The analysis was used afisher exact test, bunpaired t-test, cchi square test, *significant at p<0,05
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was performed before the Chi-Square test 
was done to find an optimal cut off point of 
the NLR. The significance criteria used was when p-values<0.05. The data obtained were recorded and then processed through the Statistical Package for the Social Sciences (SPSS) version 21.0 program for Windows.
ResultsIn total, 92 data of HNSCC patients were collected, consisting of HNSCC in the early clinical stage (n=12) and in advanced clinical stage (n=80). The majority of HNSS patients were males (88.0%). The overall characteristics of the patients in this study were shown in 
Table 1.The value of the NLR was determined based on literature, while the cutoff point of the NLR was obtained through the ROC curve analysis. NLR cutoff points based on the ROC curve analysis were 3.2 with area under the curve (AUC) value of 0.784, a sensitivity of 82.5% 
and specificity of 75.0% (Figure). Based on the cutoff point value, NLR was categorized as low if NLR was<3.2 and high if NLR was >3.2.
There was a significant difference between NLR and clinical stages in HNSCC patients (p <0.001). The direction of the relationship shown was positive, meaning  that the higher the NLR, the higher the clinical stage in patients with HNSCC; whereas the lower the NLR, the lower the clinical stage. The Odds 
Figure The NLR Cut off Point Based on ROC Curve Analysis
Table 2 The Relationship between NLR and Clinical Staging
Variable Total
Clinical Stage
p-value OR (95%CI)Early (I-II) 
n=12
Advanced (III-IV) 
n=80NLR      Low 23 (25.0) 9 (75.0) 14 (17.5) <0.001 14.1 (3.4 – 59.0)     High 69 (75.0) 3 (25.0) 66 (82.5)Note: Low NLR was <3.2 and High NLR was >3.2
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Ratio (OR) of this study was 14.1, meaning that patients who had a high NLR in HNSCC had a 14.1 higher risk in being in the advanced clinical stage compared to patients with a low NLR ratio.
DiscussionsThis study has explored the NLR as a prognostic marker in HNSCC patients. Most of our patients were males (88%), similar to study in Bulgaria11 with male and female ratio of 3.23:1. Another study in India12 also reports that HNSCC is more common in males than females, with an oral SCC and oropharyngeal SCC ratio based on gender about 1.5:1 and 2.8: 1, respectively. Moreover, a study in Pakistan12 shows head and neck carcinoma happens in 21% of males and 11% of females. This is in line with research in other places in Indonesia4,13, reporting that most of HNSCC patients are males.The risks of head and neck carcinoma increase with age, and the majority occur at the age of 50 or older. Our study has shown that the age of HNCSS patients in early is 59+17 compared to the advanced stage which is 58 +13. Although the difference in both clinical-
stage is not significantly different, there is a trend that in the advanced stage HNCSS is younger, similar to study that shows more than 50% cases of head and neck carcinoma occur at the age of >60, and 28% occurs at the age of >70. Head and neck carcinoma also occur in middle-aged patients (aged 46–55).4Interestingly, most carcinomas in this study (66.3%) are located in the larynx, and those have come at an advanced stage. This was in accordance with the result of other studies.11
The most histopathological findings in our study were moderate differentiation (47.8%), whereas carcinoma in situ is the 
least histopathological finding. This contrasts with the results of a study conducted in other places in Indonesia, that most of the HNSCC patients came with a high differentiation grade or in bad differentiation),14 or in opposite with the result in the National Referral Cancer Hospital13, that the most differentiation from HNSCC patients admitted in the hospital is the good differentiation.13 The difference in 
histopathological findings may very much depend on the various factors and need to be further explored. Meaningful results between NLR and clinical stage of HNSCC (p <0.001) in our study shows that there is a positive relationship between NLR and clinical stage of the disease; 
the higher the NLR, the higher the clinical stage of HNSCC, whereas the lower the NLR, the lower the clinical stage of HNSCC. The odds ratio (OR) in this study is 14.1; the patients with a high NLR who is suffering from HNSCC have a 14.1 times possible to have an advanced clinical stage compared to patients with a low NLR. A systematic review by Guthrie et al.15 have shown that the neutrophil-lymphocyte ratio has an independent prognostic value on tumor clinical staging.The limitations of this study are that the data on co-morbidity in HNSCC patients such as other metabolic diseases or chronic 
inflammation is lacking, as this condition may have a high value of NLR, so the confounding factor that may present could not be further assessed. Therefore, further study is needed to compare NLR in HNSCC patients with or without morbidity and prospective follow-up design study is needed to compare the NLR value pre and post-therapy among HNSCC patients.As a conclusion, NLR can be used as the prognostic marker for the clinical stage in HNSCC patients; the higher the NLR, the higher the clinical stage, with higher values is correlated with poor outcomes. 
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